Also, selective pharmacological inhibition of NLRP3 lowered aminotransferases levels and reduced hepatic inflammation in the in vivo NASH models43,44 and this effect was associated with a significant reduction in CASP1 activation44. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.